


# **BMM0413 – Aula 4: Mecanismos de resistência aos antimicrobianos**



**Nilton Lincopan, PhD**

[lincopan@usp.br](mailto:lincopan@usp.br)


<http://www.onehealthbr.com/>



**Departamento de Microbiologia – Instituto de Ciências Biomédicas  
Universidade de São Paulo, Brasil**

All images are believed to be in the public domain. If this is not the case, please email the author at [lincopan@usp.br](mailto:lincopan@usp.br) and any images will be promptly removed.

# Antimicrobianos



# ATB: Uso Clínico versus Resistência

---


Antibacteriano	Uso clínico	Resistência
Sulfonamidas	1935	1940
Penicilinas	1942	1945
Estreptomicina	1944	1958
Tetraciclina	1948	1954
Cloranfenicol	1949	1956
<b>Colistina</b>	<b>1949</b>	<b>2015*</b>
Vancomicina	1955	1982
<b>Cefalosporinas</b>	<b>1964</b>	<b>1969</b>
Quinolonas	1967	1969
<b>Carbapenems</b>	<b>1985</b>	<b>1998</b>
Ciprofloxacina	1987	1990
Linezolida	2000	2003
<b>Caz/Avibactam</b>	<b>2015</b>	<b>2015</b>

\* Mediada por plasmídeos


Weinstein A.J., *Drugs* 1980, 20:137-154.

Winkler M.L., *Antimicrob Agents Chemother*, 2015, 59:1020-1029.


# Origem da RAM



# Mecanismos de resistência



# Antimicrobianos e saúde única



# Como produzir bactéria resistentes?

---

## Pressão seletiva *in vivo*



Alta densidade de pacientes  
(superlotação)

+

Fácil circulação de patógenos

+

Condições de higiene  
deficientes

+

Amplo uso de antimicrobianos e  
desinfetantes

# Antimicrobianos: promotor, profilático, terapêutico

---



Webster P CMAJ 2009;181:21-24

*Lancet Infect Dis.* 2015, 15:1243




MICROBIOLOGY

# Fighting Obesity with Bacteria



Alan W. Walker and Julian Parkhill

Intestinal bacteria from lean humans can confer protection against fat gain in experimental mice.




# Transplante fecal: probióticos, prebióticos, fagos


---



# Antibacterianos em animais de produção



# Antibacterianos em animais de produção



**FIGURE ES-3:** Antibiotic consumption in livestock, top ten countries 2010–2030 (projected for 2030)

Source: Van Boeckel et al. 2015

*PNAS* 2015, 112: 5649-5654.

# Impacto da RAM no agronegócio e saúde única

RESEARCH

RESEARCH ARTICLE

ONE HEALTH

## Global trends in antimicrobial resistance in animals in middle-income countries

nature

Explore content ▾ About the journal ▾ Publish

[nature](#) > [news](#) > article



NEWS | 20 September 2019

## Alarm as antimicrobial resistance surges among chickens, pigs and cattle

Drug-resistant bacteria are gaining a stronghold in developing countries where meat production has soared.

### RESISTANCE HOTSPOTS

Farm animals harbour more drug-resistant bacteria in countries where meat production has increased rapidly.



©nature

Van Boeckel et al. 2019. *Science*. 365(6459). pii: eaaw1944.  
<https://www.nature.com/articles/d41586-019-02861-5>



AMERICAN  
SOCIETY FOR  
MICROBIOLOGY

Antimicrobial Agents  
and Chemotherapy



## First Characterization of CTX-M-15-Producing *Escherichia coli* Strains Belonging to Sequence Type (ST) 410, ST224, and ST1284 from Commercial Swine in South America

Ketrin C. Silva,<sup>a</sup> Marina Moreno,<sup>a</sup> Carlos Cabrera,<sup>a</sup> Beny Spira,<sup>b</sup> Louise Cerdeira,<sup>b,c</sup>  Nilton Lincopan,<sup>b,c</sup>  Andrea M. Moreno<sup>a</sup>

Department of Preventive Medicine and Animal Health, School of Veterinary Medicine, University of São Paulo, São Paulo, Brazil<sup>a</sup>; Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil<sup>b</sup>; Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil<sup>c</sup>





OPEN


# Genomic Features of High-Priority *Salmonella enterica* Serovars Circulating in the Food Production Chain, Brazil, 2000–2016

Received: 29 January 2019

Accepted: 11 June 2019

Published online: 30 July 2019


Daniel F. Monte<sup>1,4</sup>, Nilton Lincopan<sup>2,3</sup>, Hanna Berman<sup>4</sup>, Louise Cerdeira<sup>3</sup>, Shivaramu Keelara<sup>4</sup>, Siddhartha Thakur<sup>4</sup>, Paula J. Fedorka-Cray<sup>4</sup> & Mariza Landgraf<sup>1</sup>





## Endophytic Lifestyle of Global Clones of Extended-Spectrum $\beta$ -Lactamase-Producing Priority Pathogens in Fresh Vegetables: a Trojan Horse Strategy Favoring Human Colonization?

Ralf Lopes,<sup>a</sup> Danny Fuentes-Castillo,<sup>b,c</sup> Herrison Fontana,<sup>c,d</sup> Larissa Rodrigues,<sup>c,d</sup> Karine Dantas,<sup>a</sup> Louise Cerdeira,<sup>e</sup> Isabel Henriques,<sup>f,g</sup> Nilton Lincopan<sup>a,c,d</sup>





ARTICLE


Check for updates

<https://doi.org/10.1038/s41467-020-15735-6>

OPEN

# Aquaculture at the crossroads of global warming and antimicrobial resistance

Miriam Reverter<sup>1,2</sup>, Samira Sarter<sup>1,3</sup>, Domenico Caruso<sup>1</sup>, Jean-Christophe Avarre<sup>1</sup>, Marine Combe<sup>1</sup>, Elodie Peppey<sup>1,3</sup>, Laurent Pouyaud<sup>1</sup>, Sarahi Vega-Heredia<sup>1</sup>, Hugues de Verdal<sup>1,3</sup> & Rodolphe E. Gozlan<sup>1</sup>




# Origen de la RAM en ambientes acuáticos




# Oxitetraciclina en productos de acuicultura

---




J Agric Food Chem 2020 Oct 28;68(43):11908-11919.


# Tetraciclins




(Tetracycline)




(Oxytetracycline)




(Minocycline)




(Omadacycline)




(Chlortetracycline)



(Doxycycline)



(Tigecycline)



(Eravacycline)

50's

First generation

60's

Second generation

2005


(FDA)

2018

(FDA)


*Bioessays*. 2020 Aug;42(8):e2000014.

# Resistência às tetraciclinas



# Bombas de eflujo


---






Article

# Genetic Characterization of the Tetracycline-Resistance Gene *tet(X)* Carried by Two *Epilithonimonas* Strains Isolated from Farmed Diseased Rainbow Trout, *Oncorhynchus mykiss* in Chile


Christopher Concha <sup>1</sup>, Claudio D. Miranda <sup>1,2,\*</sup>, Javier Santander <sup>3</sup>  and Marilyn C. Roberts <sup>4</sup>



**Figure 1.** Colony morphotypes of the *Epilithonimonas* strains recovered from diseased rainbow trout from Chilean farms grown on TYES agar: (A) FP105; (B) FP211-J200.

# $\beta$ -lactâmicos

## Cefalosporinas



**1G:** Cefalotina (Keflin), Cefazolina

**2G:** Cefaclor

**3G:** Cefotaxima (Claforan)

Ceftriaxona (Rocephin)

Ceftazidima (Fortaz)

+ Avibactam (KPC)

Ceftiofur (Veterinário)

Cefovecina (Veterinário)

**4G:** Cefepime (Maxipime)


**5G:** Ceftarolina (MRSA)

Ceftobiprole (MRSA)



# Resistência por recombinação e $\beta$ -lactamases

---




1. Conjugação (plasmídeos)
2. Transformação
3. Transdução

*Nature Rev Microbiol* 2015, 13:42–51.


# Conjugação

---




# Resistencia por recombinação y $\beta$ -lactamasas

---




# $\beta$ -lactâmicos

---



# $\beta$ -lactamases

---



# Genes de R na natureza

---

Fuente de nuevos mecanismos en especies ambientales

CTX-M-	-----	<i>Kluyvera sp</i>
Qnr	-----	<i>Shewanella sp</i>
OXA-23	-----	<i>Acinetobacter radioresistens</i>
NDM	-----	<i>Erythrobacter litoralis</i>
OXA-48	-----	<i>Shewanella sp</i>

Gene *bla*<sub>CTX-M</sub> → β-lactamase CTX-M → Resistência:  
β-lactâmicos  
Cefalosporinas  
**Ceftiofur**  
**Cefovecina**



**GLOBAL PRIORITY LIST OF ANTIBIOTIC-RESISTANT BACTERIA  
TO GUIDE RESEARCH, DISCOVERY, AND DEVELOPMENT OF  
NEW ANTIBIOTICS**

**Priority 1: Critical**

*Acinetobacter baumannii*; carbapenem

*Pseudomonas aeruginosa*; carbapenem

*Enterobacteriaceae*\*; carbapenem, ESBL

**Priority 2: High**

*Enterococcus faecium*; vancomycin


*Staphylococcus aureus*; methicillin and vancomycin

*Helicobacter pylori*; clarithromycin

*Campylobacter* spp.; fluoroquinolone

*Salmonella*; fluoroquinolone

*Neisseria gonorrhoeae*; cephalosporin and  
fluoroquinolone



# O Problema “*One Health*”

---



- ✓ **Diseminación de patógenos de prioridad crítica**
- ✓ **Realización de antibiograma en menor proporción em MV**
- ✓ **Tratamento empírico mas frequente em MV**
- ✓ **Menos opciones terapéuticas para MDR em MV**
- ✓ **Infección hospitalar em MH y MV**

Review on antimicrobial resistance: <https://amr-review.org/home.html>





Genome Note

Genomic features of a highly virulent ceftiofur-resistant CTX-M-8-producing *Escherichia coli* ST224 causing fatal infection in a domestic cat

Meire M. Silva <sup>a</sup>, Fábio P. Sellera <sup>b</sup>  , Miriam R. Fernandes <sup>c</sup>, Quézia Moura <sup>d</sup>, Felício Garino <sup>a</sup>, Sérgio S. Azevedo <sup>a</sup>, Nilton Lincopan <sup>c, d</sup>  



Resistome:  $\beta$ -lactams (*bla*<sub>CTX-M-8</sub>), sulphonamides (*sul2*), tetracycline (*tetA*), trimethoprim (*dfrA14*), chromosomal point mutations in ParC (S80I), GyrA (S83L), and GyrB (D87N).

Virulome:


*cba*, *gad*, *ipfA*, *iroN*, *iss*, *mchF* and *tsh*.

Thoracic radiography of the cat infected by CTX-M-8-producing *E. coli*. Diffuse pulmonary opacification with air bronchograms in the ventral lung regions suggesting pneumonia.



# ESBL (CTX-M) em Animais de Companhia



---



J Antimicrob Chemother  
doi:10.1093/jac/dky173


**Identification of KPC-2-producing  
*Escherichia coli* in a companion animal:  
a new challenge for veterinary  
clinicians**

Fábio P. Sellera<sup>1†</sup>, Miriam R. Fernandes<sup>2†</sup>,  
Regina Ruiz<sup>3</sup>, Ana C. M. Falleiros<sup>3</sup>,  
Fernanda P. Rodrigues<sup>3</sup>, Louise Cerdeira<sup>2</sup> and  
Nilton Lincopan<sup>2,4\*</sup>



## Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world

Fábio P. Sellera<sup>1,2†</sup>, Luciano C. B. A. Da Silva<sup>2†</sup> and Nilton Lincopan <sup>3,4\*</sup>



# COVID-19 triggers exposure of endangered wildlife to WHO critical priority pathogens co-producing NDM and KPC carbapenemases

Fábio P. Sellera<sup>1,2,3</sup>, Brenda Cardoso<sup>1,4</sup>, Danny Fuentes-Castillo<sup>1,5</sup>, Bruna Fuga<sup>1,4,6</sup>, Fernanda


	Carbapenemase (ESBL)*	ST‡	Wildlife§	State¶	Isolation site	Diagnosis	Outcome
<i>K. pneumoniae</i> , 883b	NDM-1, KPC-2, (CTX-M-15)	1308	Magnificent frigatebird	RJ	Skin	Sepsis	Died
<i>K. pneumoniae</i> , 868	NDM-1, KPC-2, (CTX-M-15)	1308	Magnificent frigatebird	RJ	Skeletal muscle	Myositis	Died
<i>K. pneumoniae</i> , 795b	NDM-1, KPC-2, (CTX-M-15)	1308	Magnificent frigatebird	RJ	Skeletal muscle	Myositis	Died
<i>K. pneumoniae</i> , FAI130	NDM-1, KPC-2, (CTX-M-15)	1308	Green turtle	RJ	Bone	Osteomyelitis	Died
<i>K. pneumoniae</i> , FAI131	NDM-1, KPC-2, (CTX-M-15)	1308	Neotropic Cormorant	RJ	Lung	Pneumonia	Died
<i>K. pneumoniae</i> , PG2	NDM-1, (CTX-M-15)	1308	Magellanic penguin	SP	Cloacae	Cachexia	Died
<i>K. pneumoniae</i> , PG10A	NDM-1, (CTX-M-15)	1308	Magellanic penguin	SP	Cloacae	Cachexia	Died
<i>K. pneumoniae</i> , PG11	NDM-1, (CTX-M-15)	1308	Magellanic penguin	SP	Cloacae	Cachexia	Died
<i>E. coli</i> , 795a	(CTX-M-15)	10	Magnificent frigatebird	RJ	Cloacae	Sepsis	Died
<i>E. coli</i> , PG1	NDM-1	91	Magellanic penguin	SP	Cloacae	Cachexia	Died
<i>E. coli</i> , BA01	NDM-1	162	Pygmy sperm whale	SC	Lymph node	Cardiomyopathy	Died
<i>E. cloacae</i> , FAI128	NDM-1	244	Green turtle	RJ	Bone	Osteomyelitis	Died
<i>C. freundii</i> , 883c	NDM-1	1	Magnificent frigatebird	RJ	Skin	Sepsis	Died
<i>C. freundii</i> , FAI129	NDM-1	22	Green turtle	RJ	Bone	Osteomyelitis	Died
<i>C. freundii</i> , PG4	NDM-1	214	Magellanic penguin	SP	Cloacae	Cachexia	Died
<i>C. freundii</i> , FAI193	NDM-1	328	Magnificent frigatebird	RJ	Cloacae	Acute hepatitis	Died
<i>P. putida</i> , FAI194	IMP-16	128	Magnificent frigatebird	RJ	Cloacae	Sepsis	Died
<i>P. putida</i> , FAI191	IMP-16	128	Magnificent frigatebird	RJ	Cloacae	Sepsis	Survival
<i>A. baumannii</i> , FAI132	OXA-23	15	Green turtle	RJ	Bone	Osteomyelitis	Died




# Mutações

---

## Pressão seletiva *in vitro*



# Qué se disemina?




**Cepas, clones, genes, plasmídeos?**



# Resistência às fluoroquinolonas

---



# Qué se disemina?

---

## Sumatoria de eventos genéticos

Genes	IS/Tn	Plásmidos	Linajes
<b>KPC-2</b>	Tn125	IncP	ST2
OXA-48	<b>Tn4401</b>	IncA/C	<b>ST258</b>
NDM	Tn1999	Gr2	ST101
OXA-23	Tn3	IncL/M	ST131
VIM	Tn2006	Gr6	ST25
OXA-24	Tn2009	<b>IncF</b>	ST235
IMP	ISEcp1	IncH	ST111
CTX-M	IS26	IncX3	ST15

```
graph LR; KPC2[KPC-2] --- Tn4401[Tn4401]; Tn4401 --- IncF[IncF]; IncF --- ST258[ST258];
```

# 4 momentos decisivos na prescrição de antibióticos



## **O PACIENTE TEM UMA INFECÇÃO QUE REQUER ANTIBIÓTICOS?**

Leva a uma síntese das informações relevantes sobre o paciente.

## **ALGUNS DIAS DEPOIS... É POSSÍVEL TORNAR A PRESCRIÇÃO MAIS ESPECÍFICA? POSSO TROCAR A VIA DE ADMINISTRAÇÃO OU PARAR COM O ANTIBIÓTICO?**

Deve ser uma reflexão diária do prescritor. Pode ser feita entre a equipe durante a ronda.

## **SOLICITEI AS CULTURAS APROPRIADAS ANTES DE COMEÇAR O ANTIBIÓTICO? QUAL ANTIBIOTICOTERAPIA EMPÍRICA DEVO COMEÇAR?**

Análise dos fatores de risco específicos ao paciente e das prováveis causas de infecção. Garante que a administração do tratamento seja feita no tempo adequado.

## **QUAL É A DURAÇÃO DA ANTIBIOTICOTERAPIA NECESSÁRIA PARA A CONDIÇÃO DIAGNOSTICADA NESTE PACIENTE?**

Um lembrete de que duração deve ser baseada em literatura científica e não na verificação de se o paciente teve ou não resposta clínica adequada.